Category
Osimertinib
CAS Number
1421373-66-1
Molecular Formula
C29H37N7O5S
Molecular Weight
595.71 g/mol
Synonym

N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide Mesylate; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide Methanesulfonate;

Keywords
Pharmaceutical Standards
Intermediates
Fine Chemicals
Amines
Aromatics
sulphur and selenium compounds
Slide_1
Purity:

Above - 95.0%

Technical Data:

We will provide complete documentation support for every Standard Material. All analytical reports such as ¹H NMR, ¹³C NMR, Mass, FT-IR, HPLC Purity/GC Purity/QNMR Purity, Water content by KF/ Loss on Drying/TGA (Thermo-gravimetric Analysis). Certificate of Analysis with potency report. Each Standard Material SER (Structure Elucidation Report) with NMR, Mass, IR spectral interpretation. This whole analytical document can be included in eCTD, ANDA, DMF submissions to regulatory agencies.

Osimertinib Mesylate is an oral, third-generation EGFR tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations, including T790M-positive tumors resistant to earlier-generation EGFR inhibitors, by selectively targeting both sensitizing and resistance mutations while sparing wild-type EGFR, thereby improving efficacy and safety in advanced or metastatic NSCLC patients.